The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study)
| Autor: | Yeung-Chul Mun, Chang-Ki Min, Ho Sup Lee, Sung-Soo Yoon, Seong Kyu Park, Won Sik Lee, Yoo Jin Lee, Su-Hee Cho, Yong Park, Jae-Cheol Jo, Ho-Jin Shin, Sung-Nam Lim, Young Rok Do, Je-Jung Lee, Kihyun Kim, Sung-Hyun Kim, Dok Hyun Yoon, Hyo Jung Kim, Hyeon-Seok Eom, Soo Mee Bang, Mark Hong Lee, Jinmi Kim, Jin Seok Kim, Jun Ho Yi, Min Kyoung Kim, Jae Hoon Lee |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Chemotherapy Multivariate analysis Hematology business.industry medicine.medical_treatment General Medicine medicine.disease Clinical Practice 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis Internal medicine medicine business Adverse effect Dexamethasone Multiple myeloma 030215 immunology Lenalidomide medicine.drug |
| Zdroj: | Annals of Hematology. 99:309-319 |
| ISSN: | 1432-0584 0939-5555 |
| DOI: | 10.1007/s00277-019-03904-7 |
| Popis: | Although lenalidomide plus dexamethasone (RD) is a therapeutic option for relapsed/refractory multiple myeloma (RRMM), limited real-world clinical data exist. The purpose of this study was to estimate efficacy and safety of RD in RRMM patients of the clinical practice. Data from patients at 25 university hospitals in South Korea between October 2009 and December 2016 were collected retrospectively. We report the effectiveness and safety of RD in 546 RRMM patients in routine clinical practice in South Korea. Patients (median age, 65 years) typically received median 7 cycles of RD, and 184 (33.7%) patients were treated with 10 or more cycles of RD. Patients with renal impairment (CLCr |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink